Evidence map›Paper›PMID 39293403›Full record

ArticleCell reports. Medicine2024

Single-cell AI-based detection and prognostic and predictive value of DNA mismatch repair deficiency in colorectal cancer.

Marta Nowak, Faiz Jabbar, Ann-Katrin Rodewald, Luciana Gneo, Tijana Tomasevic, Andrea Harkin, Tim Iveson, Mark Saunders, Rachel Kerr, Karin Oein and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Marta NowakDepartment of Pathology and Molecular Pathology, Zurich, Zurich, Switzerland.
Faiz JabbarCancer Genomics and Immunology Group, The Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK.
Ann-Katrin RodewaldDepartment of Pathology and Molecular Pathology, Zurich, Zurich, Switzerland.
Luciana GneoCancer Genomics and Immunology Group, The Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK.
Tijana TomasevicCancer Genomics and Immunology Group, The Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK.
Andrea HarkinCRUK Glasgow Clinical Trials Unit, University of Glasgow, Glasgow, UK.
Tim IvesonUniversity of Southampton, Southampton, UK.
Mark SaundersThe Christie NHS Foundation Trust, Manchester, UK.
Rachel KerrDepartment of Oncology, University of Oxford, Oxford, UK.
Karin OeinGlasgow Tissue Research Facility, University of Glasgow, Queen Elizabeth University Hospital, Glasgow, UK.
Noori MakaGlasgow Tissue Research Facility, University of Glasgow, Queen Elizabeth University Hospital, Glasgow, UK.
Jennifer HayGlasgow Tissue Research Facility, University of Glasgow, Queen Elizabeth University Hospital, Glasgow, UK.
Joanne EdwardsSchool of Cancer Sciences, University of Glasgow, Glasgow, UK.
Ian TomlinsonDepartment of Oncology, University of Oxford, Oxford, UK.
Owen SansomCRUK Beatson Institute of Cancer Research, Garscube Estate, Glasgow, UK.
Caroline KellyCRUK Glasgow Clinical Trials Unit, University of Glasgow, Glasgow, UK.
Francesco PezzellaRadcliffe Department of Medicine, University of Oxford, Oxford, UK.
David KerrNuffield Department of Clinical and Laboratory Sciences, University of Oxford, Oxford, UK.
Alistair EastonDepartment of Oncology, University of Oxford, Oxford, UK.
Enric DomingoDepartment of Oncology, University of Oxford, Oxford, UK.
TransSCOT group
Viktor H KoelzerDepartment of Pathology and Molecular Pathology, Zurich, Zurich, Switzerland; Department of Oncology, University of Oxford, Oxford, UK; Nuffield Department of Medicine, University of Oxford, Oxford, UK; Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
David N ChurchCancer Genomics and Immunology Group, The Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK; Oxford NIHR Comprehensive Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Electronic address: dchurch@well.ox.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Testing for DNA mismatch repair deficiency (MMRd) is recommended for all colorectal cancers (CRCs). Automating this would enable precision medicine, particularly if providing information on etiology not captured by deep learning (DL) methods. We present AIMMeR, an AI-based method for determination of mismatch repair (MMR) protein expression at a single-cell level in routine pathology samples. AIMMeR shows an area under the receiver-operator curve (AUROC) of 0.98, and specificity of ≥75% at 98% sensitivity against pathologist ground truth in stage II/III in two trial cohorts, with positive predictive value of ≥98% for the commonest pattern of somatic MMRd. Lower agreement with microsatellite instability (MSI) testing (AUROC 0.86) reflects discordance between MMR and MSI PCR rather than AIMMeR misclassification. Analysis of the SCOT trial confirms MMRd prognostic value in oxaliplatin-treated patients; while MMRd does not predict differential benefit of chemotherapy duration, it correlates with difference in relapse by regimen (P

Indexed as

Colorectal NeoplasmsDNA Mismatch RepairMicrosatellite InstabilitySingle-Cell AnalysisAgedFemaleHumansMaleMiddle AgedPredictive Value of TestsPrognosisROC CurveAIcolorectal cancerdigital pathologymicrosatellite instabilitymismatch repair deficiency

Identifiers

PMID39293403
PMCPMC11525017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.